Mizuho Securities Upgrades Amedisys (AMED) to Buy; Sell-Off Excessive

November 7, 2016 7:48 AM EST
Get Alerts AMED Hot Sheet
Price: $46.35 +1.53%

Rating Summary:
    6 Buy, 9 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade AMED Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Mizuho Securities upgraded Amedisys (NASDAQ: AMED) from Neutral to Buy with a price target of $47.00, calling the sell-off after the COO resigned 'excessively overdone'.

Analyst Sheryl Skolnick commented, "AMED's shares dove Friday in concert with another C-Suite change at the company, this time at the COO level. But we spoke with CEO Kusserow after the call and, combined with his answers to our questions during the call, we're more comfortable with the reasons for the change and with our estimates. Thus, we see the sell-off as excessively overdone, reiterate our $47 PT and upgrade the shares to Buy from Neutral."

For an analyst ratings summary and ratings history on Amedisys click here. For more ratings news on Amedisys click here.

Shares of Amedisys closed at $38.20 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Upgrades, Upgrades

Add Your Comment